Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-label, Single-arm Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ocrelizumab in Chinese Patients With Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis

NCT07483450 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT07483450
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07483450 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-label, Single-arm Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ocrelizumab in Chinese Patients With Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis
Lead sponsor
Hoffmann-La Roche
Phase
Phase 4
Overall status
Active, not recruiting
Start date
July 4, 2025
Completion date
December 31, 2028
Enrollment
60 (estimated)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

primary progressive multiple sclerosis, relapsing multiple sclerosis